IRCT20130313012810N7 IRCT 2023-01-09 Behestan Daru Co Comparative bioequivalence study of the Amiodarone 200-mg Tablets manufactured by Behestan Pharmaceutical Company Comparative bioequivalence study of the Amiodarone 200-mg Tablets manufactured by Behestan Pharmaceutical Company 2022-12-26 anticipated 24 Complete https://irct.ir/trial/67522 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other. Bioequivalence bioequivalence study. Intervention group: This study examines the bioequivalence of amiodarone tablets produced by a domestic company with a foreign brand sample. We have only one intervention group and there is no control group. The intervention group, which includes healthy, fasting male volunteers, will receive a single dose, a 200 mg tablet manufactured by the pharmaceutical company Behestan and Sanofi brand, in two 72-hour periods with an interval of one month, on the first day of the study. In 14 different time periods up to 72 hours after taking the medicine, blood samples will be taken from the volunteers in the amount of 3 ml each time, that is, a total of 42 ml within 72 hours. The training that will be given to the volunteers includes avoiding the consumption of drinks containing alcohol and xanthine and other interfering drugs in the prescription drug from 48 hours before the start of the study until the end of the study. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Industry license will be required